Amarin Corp Ads (AMRN)
$6.00 0.19 (3.27%)
4:24 EDT AMRN Stock Quote Delayed 20 Minutes
Previous Close $5.81
Market Cap 1.76B
PE Ratio -
Volume (Avg. Vol.) 1,887
Day's Range 5.81 - 5.81
52-Week Range 3.95 - 26.12
Dividend & Yield N/A (N/A)
AMRN Stock Predictions, Articles, and Amarin Corp Ads News
- From InvestorPlace
- From the Web
Amarin shares fell 70% on the day, while we're already talking about another $2 trillion plan. Here's the stock market today.
Amarin (AMRN) news for Tuesday concerning a generic rival lawsuit over one of its drugs has AMRN stock taking a nosedive.
The M&A market could bounce back in 2020, and as it does, investors should keep an eye on these seven buyout targets.
n late February, I argued that the company’s move to double its U.S. sales force to 800 to meet the demand for Vascepa, along with the future approvals of the drug in Europe, Canada and elsewhere, made Amarin stock a smart buy despite the apparent risk.
Amarin was supposed to have a huge 2020 after securing a key FDA approval. Instead, the stock is going down, and the CEO is selling shares.
Amarin stock has hit a wall, potentially because of generics litigation. But I think this has been an overreaction. Here’s a look at why.
Tuesday's big stock charts feature three big winners in Monday's big rally — all of which have hopes for further upside ahead.
Amarin stock has declined by nearly a quarter so far in 2020 — on little news. That lower valuation makes AMRN an intriguing candidate on the dip.
Amarin, Bank of America, Carnival Cruise and Lowe's were our top stock trades from Wednesday. That said, here's a look at the charts.
Amarin stock is not reacting favorably to its earnings and revenue beat. What will it take for the stock to regain momentum?
I’d expect based on Q3 2019 that the company will report strong revenue growth in the fourth quarter, but the real show will come in Q2 2020 and onward as Amarin's expanded salesforce meets with doctors across the country.
By Ian Cooper
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
Despite substantial attention on Amarin stock due to the underlying company’s Vascepa drug receiving FDA approval, shares haven’t looked great in 2020. Is this a discounted opportunity or a sign to stay away?
As AMRN stock's future will likely depend on how strong sales of Vascepa will be, investors may want to wait for the upcoming Q4 numbers before investing in Amarin shares.
Vascepa's growth trajectory will sustain robust momentum in 2020, and as it does, Amarin stock will stay in rally mode.
By Thomas Niel
Also, the courts could rule against Amarin's favor in the patent suit. Yet, with material upside potential, Amarin stock could be worth the risk.
The biggest unknown weighing on Amarin stock is how long the decision to take Vascepa will be up to patients, rather than experts.
Bears are in control of Amarin stock, and selling pressure has driven the price down. But Vascepa will drive huge success for Amarin in 2020.
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader